Comparison of the Efficacy of Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Type 2 Diabetes
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgad714 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von So Young Park und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Kyung Hee University Hospital, Seoul 02447, Republic of Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Drug Therapy, Combination, Ezetimibe. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Kyung Hee University, Celltrion.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Context
Low-density lipoprotein cholesterol (LDL-C)-lowering therapy is considerably important in preventing cardiovascular disease (CVD) among patients with diabetes. Studies comparing CVD, stroke, and mortality outcomes of low- or moderate-intensity statins with ezetimibe combination therapy and high-intensity statin monotherapy in patients with diabetes remain lacking.
Objective
This study compared the primary prevention effect of myocardial infarction (MI), stroke, and all-cause death between combination therapy of low- or moderate-intensity statins and ezetimibe and high-intensity statin monotherapy in patients with diabetes using the Korean National Health Insurance claims database.
Methods
Patients aged ≥20 years with type 2 diabetes and dyslipidemia were enrolled. The combination therapy of low- or moderate-intensity statin and ezetimibe was compared with high-intensity statin monotherapy after a propensity score–matched analysis. The incidence of composite outcomes consisting of MI, stroke, and all-cause death and each component were analyzed.
Results
In moderate-intensity statin therapy with ezetimibe combination therapy, LDL-C (74 ± 37.9 mg/dL vs 80.8 ± 38.8 mg/dL, P < .001) and the incidence of composite outcomes were lower (hazard ratio 0.85, 95% CI 0.74-0.98) than those in high-intensity statin monotherapy. Meanwhile, no significant difference was observed in the LDL-C levels and composite outcomes between low-intensity statins with ezetimibe combination therapy and high-intensity statin monotherapy.
Conclusion
Adding ezetimibe to a moderate-intensity statin in patients with type 2 diabetes has a greater LDL-C–lowering effect and greater primary prevention of composite outcomes than that of high-intensity statin monotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Kyung Hee University Hospital, Seoul 02447, Republic of Korea.
- Department of Endocrinology & Metabolism, Kyung Hee University School of Medicine, Seoul 02453, Republic of Korea.
- Department of Endocrinology and Metabolism, Kyung Hee University Hospital at Gangdong, Seoul 05278, Republic of Korea.
ORCID-Profile: Ji Eun Jun, In-Kyung Jeong, You-Cheol Hwang
Förderung
- Kyung Hee University
- Celltrion
Zitieren
APA
Park, S. Y., Jun, J. E., Jeong, I. K., Ahn, K. J., Chung, H. Y., & Hwang, Y. C. (2024). Comparison of the Efficacy of Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad714
Vancouver
Park SY, Jun JE, Jeong IK, Ahn KJ, Chung HY, Hwang YC. Comparison of the Efficacy of Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad714
BibTeX
@article{Park2024,
author = {Park, So Young and Jun, Ji Eun and Jeong, In-Kyung and Ahn, Kyu Jeung and Chung, Ho Yeon and Hwang, You-Cheol},
title = {Comparison of the Efficacy of Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Type 2 Diabetes},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgad714}
}
EUVIMED